Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Rapporto sulle azioni

Cap. di mercato: US$6.9b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Jazz Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Jazz Pharmaceuticals' Il CEO è Bruce Cozadd, nominato in Jan2003, e ha un mandato di 21.58 anni. la retribuzione annua totale è $ 15.34M, composta da 7.8% di stipendio e 92.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.51% delle azioni della società, per un valore di $ 35.06M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5 anni e 11.3 anni.

Informazioni chiave

Bruce Cozadd

Amministratore delegato

US$15.3m

Compenso totale

Percentuale dello stipendio del CEO7.8%
Mandato del CEO21.7yrs
Proprietà del CEO0.5%
Durata media del management5yrs
Durata media del Consiglio di amministrazione11.3yrs

Aggiornamenti recenti sulla gestione

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Recent updates

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bruce Cozadd rispetto agli utili di Jazz Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$395m

Mar 31 2024n/an/a

US$331m

Dec 31 2023US$15mUS$1m

US$415m

Sep 30 2023n/an/a

US$80m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$156m

Dec 31 2022US$17mUS$1m

-US$224m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$450m

Dec 31 2021US$16mUS$1m

-US$330m

Sep 30 2021n/an/a

-US$161m

Jun 30 2021n/an/a

US$40m

Mar 31 2021n/an/a

US$518m

Dec 31 2020US$13mUS$1m

US$239m

Sep 30 2020n/an/a

US$179m

Jun 30 2020n/an/a

US$133m

Mar 31 2020n/an/a

US$280m

Dec 31 2019US$15mUS$1m

US$523m

Sep 30 2019n/an/a

US$609m

Jun 30 2019n/an/a

US$656m

Mar 31 2019n/an/a

US$486m

Dec 31 2018US$11mUS$979k

US$447m

Sep 30 2018n/an/a

US$520m

Jun 30 2018n/an/a

US$434m

Mar 31 2018n/an/a

US$447m

Dec 31 2017US$10mUS$950k

US$488m

Compensazione vs Mercato: La retribuzione totale di Bruce ($USD 15.34M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.39M ).

Compensazione vs guadagni: La retribuzione di Bruce è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Bruce Cozadd (60 yo)

21.7yrs

Mandato

US$15,341,235

Compensazione

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Bruce Cozadd
Co-Founder21.7yrsUS$15.34m0.51%
$ 35.0m
Renee Gala
President & COOless than a yearUS$5.43m0.027%
$ 1.9m
Patricia Carr
Senior VP & Chief Accounting Officer5.1yrsUS$1.40mNessun dato
Neena Patil
Executive VP & Chief Legal Officer5.2yrsUS$3.88m0.018%
$ 1.2m
Robert Iannone
Executive VP5.3yrsUS$4.98m0.046%
$ 3.1m
Philip Johnson
Executive VP & CFOless than a yearNessun dato0.019%
$ 1.3m
Andrea Flynn
VP & Head of Investor Relationsno dataNessun datoNessun dato
Heidi Manna
Executive VP & Chief People Officer5.8yrsNessun datoNessun dato
Jed Black
Senior Vice President of Sleep & CNS Medicineno dataNessun datoNessun dato
Samantha Pearce
Executive VP & Chief Commercial OfficerChief Commercial Officer4.5yrsNessun dato0.010%
$ 710.4k
John Miller
Senior Vice President of Corporate Strategy5yrsNessun datoNessun dato
Mary Henderson
Senior Vice President of Technical Operations1.1yrsNessun dato0.0021%
$ 141.8k

5.0yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di JAZZ è esperto e expertise (durata media dell'incarico 5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Bruce Cozadd
Co-Founder21.7yrsUS$15.34m0.51%
$ 35.0m
Kenneth O'Keefe
Independent Director20.7yrsUS$513.77k0.045%
$ 3.1m
Seamus Mulligan
Independent Director12.7yrsUS$531.27k1.89%
$ 129.7m
Norbert Riedel
Independent Director11.3yrsUS$533.77k0.020%
$ 1.4m
Patrick Gerald Enright
Independent Director15.2yrsUS$526.27k0.034%
$ 2.3m
Patrick Kennedy
Independent Directorless than a yearNessun datoNessun dato
Rick Winningham
Lead Independent Director14.3yrsUS$571.27k0.015%
$ 994.0k
Jennifer Cook
Independent Non-Executive Director3.8yrsUS$533.77k0.0088%
$ 599.4k
Laura Hamill
Independent Directorless than a yearNessun dato0.0024%
$ 166.5k
Heather McSharry
Independent Director11.3yrsUS$543.77k0.025%
$ 1.7m
Mark Smith
Independent Non-Executive Director3.8yrsUS$521.27k0.0088%
$ 599.4k
Anne O'Riordan
Independent Director5.6yrsUS$523.77k0.018%
$ 1.2m

11.3yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di JAZZ è composto da personale esperto e esperto (durata media dell'incarico 11.3 anni).